Tyra Biosciences stock tumbles 30% on phase 2 trial results

2 outlets ·Stocks

0 left · 0 center · 1 right

How each outlet headlined it

• Investing.com Stocks

  Tyra Biosciences stock tumbles 30% on phase 2 trial results
  
• Investor's Business Daily right

  Tyra stock plummeted to a 10-month low Wednesday on mixed test results for its experimental bladder cancer treatment. The post Tyra Plummets To 10-Month Low On Mixed Bladder Cancer Results appeared first on Investor's Business Daily.